JP2005514327A - レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体 - Google Patents

レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体 Download PDF

Info

Publication number
JP2005514327A
JP2005514327A JP2003513557A JP2003513557A JP2005514327A JP 2005514327 A JP2005514327 A JP 2005514327A JP 2003513557 A JP2003513557 A JP 2003513557A JP 2003513557 A JP2003513557 A JP 2003513557A JP 2005514327 A JP2005514327 A JP 2005514327A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
independently
diisopropyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003513557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514327A5 (https=
Inventor
グレーセ，ティモシー，アラン
ガーディニアー，ケビン，エム．
ボーム，マーカス，エフ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JP2005514327A publication Critical patent/JP2005514327A/ja
Publication of JP2005514327A5 publication Critical patent/JP2005514327A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003513557A 2001-07-20 2002-07-18 レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体 Pending JP2005514327A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30695101P 2001-07-20 2001-07-20
PCT/US2002/023017 WO2003007950A1 (en) 2001-07-20 2002-07-18 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators

Publications (2)

Publication Number Publication Date
JP2005514327A true JP2005514327A (ja) 2005-05-19
JP2005514327A5 JP2005514327A5 (https=) 2005-12-22

Family

ID=23187597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003513557A Pending JP2005514327A (ja) 2001-07-20 2002-07-18 レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体

Country Status (7)

Country Link
US (1) US20040248913A1 (https=)
EP (1) EP1414450A1 (https=)
JP (1) JP2005514327A (https=)
AU (1) AU2002319583B2 (https=)
CA (1) CA2452541A1 (https=)
MX (1) MXPA04000613A (https=)
WO (1) WO2003007950A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators
WO2011103536A1 (en) * 2010-02-19 2011-08-25 Arizona Board Of Regents Multifunctional radical quenchers and their use
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
AU2016220153B2 (en) 2015-02-17 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
WO1997012853A1 (en) * 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
AU7586600A (en) * 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
EP1368296A1 (en) * 2001-03-14 2003-12-10 Eli Lilly And Company Fluorinated trienes and their use as rxr modulators

Also Published As

Publication number Publication date
MXPA04000613A (es) 2004-05-05
US20040248913A1 (en) 2004-12-09
CA2452541A1 (en) 2003-01-30
WO2003007950A1 (en) 2003-01-30
EP1414450A1 (en) 2004-05-06
AU2002319583B2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
DE60204674T2 (de) Retinoid x rezeptormodulatoren
EP0873295B1 (en) Dimer-selective rxr modulators and methods for their use
US6593493B1 (en) RXR modulators with improved pharmacologic profile
US6083977A (en) Trienoic retinoid compounds and methods
EP0800503B1 (en) Novel trienoic retinoid compounds and methods
JP2001055367A (ja) ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
FR2787789A1 (fr) Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
RU2166499C2 (ru) Ретиноиды
JP2004526725A (ja) フッ化トリエンおよびｒｘｒモジュレータとしてのその使用
JPH01301661A (ja) 新規ピリジル誘導体
US5998654A (en) Retinoic acid receptor antagonist compounds and methods
AU2002255732A1 (en) Fluorinated trienes and their use as RXR modulators
US7019034B2 (en) Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en) 3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
JP2005514327A (ja) レチノイドｘレセプターモジュレータとしての（ピリジニルおよびピミジル）トリエン酸誘導体
US6005007A (en) Retinoids, methods for their production and use
DE69513689T2 (de) Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
AU2002319583A1 (en) (Pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid X receptor modulators
FR2849849A1 (fr) Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
EP0879223B1 (fr) Derives polycycliques aromatiques de type retinoide, leur procede de preparation et leur utilisation pour la fabrication de compositions pharmaceutiques et cosmetiques
JP2002511053A (ja) レチノイド型四環芳香族化合物の製造方法及び利用
KR20060079254A (ko) 다이머-선택적 ｒｘｒ 변조물질 및 그의 사용방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090326